Compare WASH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WASH | ENGN |
|---|---|---|
| Founded | 1800 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.9M | 605.5M |
| IPO Year | N/A | N/A |
| Metric | WASH | ENGN |
|---|---|---|
| Price | $29.59 | $8.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $30.25 | $22.71 |
| AVG Volume (30 Days) | 115.1K | ★ 248.6K |
| Earning Date | 01-28-2026 | 12-22-2025 |
| Dividend Yield | ★ 7.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $117,341,000.00 | N/A |
| Revenue This Year | $57.78 | N/A |
| Revenue Next Year | $8.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.95 | $2.65 |
| 52 Week High | $34.13 | $11.14 |
| Indicator | WASH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 56.96 |
| Support Level | $30.04 | $7.57 |
| Resistance Level | $30.40 | $9.81 |
| Average True Range (ATR) | 0.51 | 0.72 |
| MACD | -0.20 | 0.03 |
| Stochastic Oscillator | 11.50 | 55.73 |
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, and wealth management and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.